A single supratentorial high-grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
07 2020
Historique:
received: 03 02 2020
revised: 02 04 2020
accepted: 17 04 2020
pubmed: 10 5 2020
medline: 25 8 2020
entrez: 9 5 2020
Statut: ppublish

Résumé

Here, we present a patient with high-grade neuroepithelial tumors with mutations in the BCL6 corepressor BCOR (HGNET-BCOR), a rare, highly malignant brain tumor with poor prognosis. The patient underwent gross total tumor resection (GTR), high-dose chemotherapy, and, after local relapse, GTR, proton radiation, and chemotherapy. After a 7.5 year-long complete remission, the tumor recurred locally, was treated by GTR, and responded to temozolomide treatment. In addition to an internal tandem duplication in BCOR common to the majority of HGNET-BCOR cases, molecular analysis revealed a second BCOR mutation in this tumor: a frame shift mutation. The combination of these mutations was associated with relatively low BCOR expression compared to other HGNET-BCOR cases.

Identifiants

pubmed: 32383815
doi: 10.1002/pbc.28384
doi:

Substances chimiques

BCOR protein, human 0
Proto-Oncogene Proteins 0
Repressor Proteins 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28384

Informations de copyright

© 2020 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.

Références

Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016;164(5):1060-1072.
Ferris SP, Velazquez Vega J, Aboian M, et al. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathol. 2019;30(1):46-62.
Friedrich C, von Bueren AO, von Hoff K, et al. Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro Oncol. 2013;15(2):224-234.
Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-474.
Paret C, Russo A, Otto H, et al. Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy. Oncotarget. 2017;8(69):114210-114225.
Paret C, Theruvath J, Russo A, et al. Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy. Oncotarget. 2016;7(50):83378-83391.
Appay R, Macagno N, Padovani L, et al. HGNET-BCOR tumors of the cerebellum: clinicopathologic and molecular characterization of 3 cases. Am J Surg Pathol. 2017;41(9):1254-1260.
Yoshida Y, Nobusawa S, Nakata S, et al. CNS high-grade neuroepithelial tumor with BCOR internal tandem duplication: a comparison with its counterparts in the kidney and soft tissue. Brain Pathol. 2018;28(5):710-720.
Kirkman MA, Pickles JC, Fairchild AR, et al. Early wound site seeding in a patient with central nervous system high-grade neuroepithelial tumor with BCOR alteration. World Neurosurg. 2018;116:279-284.
Al-Battashi A, Al Hajri Z, Perry A, Al-Kindi H, Al-Ghaithi I. A cerebellar high-grade neuroepithelial tumour with BCOR alteration in a five-year-old child: a case report. Sultan Qaboos Univ Med J. 2019;19(2):e153-e156.
Haberler C, Reiniger L, Rajnai H, et al. Case of the month 1-2019: CNS high-grade neuroepithelial tumor with BCOR alteration. Clin Neuropathol. 2019;38(1):4-7.
Roy A, Kumar V, Zorman B, et al. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nat Commun. 2015;6:8891.
Tanaka T, Nakajima-Takagi Y, Aoyama K, et al. Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies. J Exp Med. 2017;214(10):2901-2913.

Auteurs

Juliane Bremer (J)

Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.
Institute of Neuropathology, University Hospital RWTH Aachen, Aachen, Germany.

Raimund Kottke (R)

Department of Diagnostic Imaging, University Children's Hospital Zurich, Zurich, Switzerland.

Pascal D Johann (PD)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.

Katja von Hoff (K)

Department of Pediatric Hematology and Oncology, Charité University Medicine, Berlin, Germany.

Pierluigi Brazzola (P)

Istituto Pediatrico della Svizzera Italiana, Bellinzona, Switzerland.

Michael A Grotzer (MA)

Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.

Marcel Kool (M)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Elisabeth Rushing (E)

Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.

Nicolas U Gerber (NU)

Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH